Cartesian Therapeutics Announces New Employment Inducement Grants
The employee options vest through October 1, 2030, rather than becoming fully vested at grant.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cartesian Therapeutics (RNAC) granted options to purchase 121,900 common shares to four new employees on October 1, 2026.
The options have an exercise price of $7.22, matching the closing share price on the Nasdaq Global Market on the grant date, and a ten-year term. They vest 25% on October 1, 2027, followed by thirty-six substantially equal monthly installments, reaching full vesting on October 1, 2030.
The board approved the awards under the Amended and Restated 2018 Employment Inducement Incentive Award Plan. The grants were employment inducements under Nasdaq Listing Rule 5635(c)(4).
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Options for 121,900 common shares at a $7.22 exercise price create potential dilution upon exercise.
Key Figures
- Options granted
- 121,900 shares
- Aggregate options granted to four new employees
- Exercise price
- $7.22 per share
- Grant-date closing trading price
- Initial vesting
- 25%
- Vests on October 1, 2027
- Monthly vesting installments
- 36
- After the initial vesting date
- Full vesting date
- October 1, 2030
- Options become fully vested
- Option term
- Ten years
- Term of the options
Key Terms
exercise price financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
FREDERICK, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to four new employees. On October 1, 2026, the Company issued to these employees options to purchase an aggregate of 121,900 shares of the Company’s common stock with an exercise price of
About Cartesian Therapeutics
Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.
Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com
Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What employee inducement options did Cartesian Therapeutics grant?
Cartesian Therapeutics granted four new employees options to purchase 121,900 common shares on October 1, 2026, at an exercise price of $7.22. The exercise price matched the closing trading price on the Nasdaq Global Market on the grant date.
When do Cartesian Therapeutics' October 2026 employee options vest?
The options vest 25% on October 1, 2027, then in thirty-six substantially equal monthly installments until fully vested on October 1, 2030. They have a ten-year term.